Idiopathic Pulmonary Fibrosis
426
47
65
243
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
103 trials with published results (24%)
Research Maturity
243 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.3%
44 terminated out of 426 trials
84.7%
-1.8% vs benchmark
12%
52 trials in Phase 3/4
42%
103 of 243 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 243 completed trials
Clinical Trials (426)
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
Real-life-persistence to Antifibrotic Treatments
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
NAL ER IPF Respiratory Function and Safety Study
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Validation of the C-mo System - Cough Monitoring
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)